Samuel Gurevich, MD
Pulmonary Disease · Weston, FLNPI 1134109044
Payments from drug & device makers
Across 30 payments — averaging $39.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avadel CNS Pharmaceuticals, LLC$200
- GSK$159
- Alcon$155
- Jazz Pharmaceuticals Inc.$150
- AstraZeneca$118
- Grifols USA, LLC$65
- plus $326 from 12 others
What the payments were for
- Consulting fees$35030%
- Travel & lodging$121%
- Food & beverage$81069%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avadel CNS Pharmaceuticals, LLC | 1 | $200 |
| GSK | 7 | $159 |
| Alcon | 2 | $155 |
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| AstraZeneca | 1 | $118 |
| Grifols USA, LLC | 5 | $65 |
| Intuitive Surgical | 1 | $65 |
| Boehringer Ingelheim | 2 | $50 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Lungpacer Medical USA Inc | 1 | $31 |
| Eisai Inc. | 1 | $28 |
| Getinge USA Sales, LLC | 1 | $26 |
| Genentech USA, Inc. | 1 | $20 |
| Covidien LP | 1 | $17 |
| Merck | 1 | $17 |
| Novartis | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,172 in reported general payments places this provider in the 30th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 77 | $1,029,517 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 196 | $152,757 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $109,546 |
| Dupixent SyringeDupilumab | 13 | $44,641 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $37,928 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $34,202 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $18,157 |
| NeuproRotigotine | 14 | $16,728 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $10,544 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $8,724 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $8,621 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $5,625 |
| BreynaBudesonide/Formoterol Fumarate | 23 | $5,587 |
| DalirespRoflumilast | 11 | $4,637 |
| Arnuity ElliptaFluticasone Furoate | 11 | $4,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $50 | $1,040,06199 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $159 | $229,333340 claims |
| Grifols USA, LLCProlastin C | $65 | $109,54611 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Daliresp | $118 | $28,41963 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Weston
- Franck RahaghiWeston$1.5M
- Anas HadehWeston$844K
- Jinesh MehtaWeston$645K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.